Astellas Pharma Ltd. Sustainability Profile
Astellas Pharma Ltd., a leading global pharmaceutical company headquartered in the United Kingdom, is renowned for its innovative approach to healthcare. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including Europe, North America, and Asia. Specialising in areas such as urology, oncology, and immunology, Astellas is committed to developing unique therapies that address unmet medical needs. The company’s core products, including the prostate cancer treatment Xtandi and the antifungal agent Cresemba, exemplify its dedication to advancing patient care. With a robust pipeline and a focus on research and development, Astellas Pharma Ltd. continues to solidify its position as a prominent player in the global pharmaceutical industry, recognised for its contributions to innovative healthcare solutions.
DitchCarbon Score
How does Astellas Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas Pharma Ltd.'s score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astellas Pharma Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Astellas Pharma Inc., which may influence its climate commitments and reporting practices. While Astellas Pharma Ltd. has not outlined specific reduction targets or achievements, it is important to note that its climate initiatives and performance metrics are inherited from Astellas Pharma Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are critical frameworks for setting and achieving climate goals. As a part of its corporate family, Astellas Pharma Ltd. aligns with broader industry standards and commitments to reduce greenhouse gas emissions, although specific targets and metrics have not been disclosed at this level. The company’s climate strategy may reflect the overarching goals set by its parent organization, Astellas Pharma Inc., which is actively engaged in sustainability efforts. In summary, while Astellas Pharma Ltd. does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate action and sustainability through its affiliation with Astellas Pharma Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Astellas Pharma Ltd.'s Industry?
How Carbon Intensive is Astellas Pharma Ltd.'s Location?
Astellas Pharma Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Astellas Pharma Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
